REGISTERED NUMBER: 09053097 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MAY 2026

FOR

PHARMA FIRST LTD

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

Mrs V Patel

P Patel

REGISTERED OFFICE:

Admiral House

Waterfront East

Brierley Hill

West Midlands

DY5 1XG

REGISTERED NUMBER:

09053097 (England and Wales)

ACCOUNTANTS:

Blackthorns

Admiral House

Waterfront East

Brierley Hill

West Midlands

DY5 1XG

FIXED ASSETS

Tangible assets

4

12

16

CURRENT ASSETS

Debtors

5

29,311

27,429

Cash at bank

1,713

2,039

31,024

29,468

CREDITORS

Amounts falling due within one year

6

19,015

6,088

NET CURRENT ASSETS

12,009

23,380

TOTAL ASSETS LESS CURRENT LIABILITIES

12,021

23,396

CREDITORS

Amounts falling due after more than one year

7

11,495

23,403

NET ASSETS/(LIABILITIES)

526

(7

)

CAPITAL AND RESERVES

Called up share capital

20

20

Retained earnings

506

(27

)

526

(7

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 16 September 2026 and were signed on its behalf by:

Mrs V Patel - Director

1.	STATUTORY INFORMATION

Pharma First Ltd is a private company, limited by shares, registered in England and Wales, registered number 09053097. Its registered office is Admiral House, Waterfront East, Brierley Hill, DY5 1XG.

The financial statements are presented in Sterling, which is the functional currency of the company.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc

-

25% on reducing balance

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2025 - 2 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 June 2025

and 31 May 2026

399

DEPRECIATION

At 1 June 2025

383

Charge for year

4

At 31 May 2026

387

NET BOOK VALUE

At 31 May 2026

12

At 31 May 2025

16

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.5.26

31.5.25

£

£

Other debtors

29,311

27,429

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.5.26

31.5.25

£

£

Bank loans and overdrafts

11,908

-

Trade creditors

168

246

Taxation and social security

5,286

4,428

Other creditors

1,653

1,414

19,015

6,088

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31.5.26

31.5.25

£

£

Bank loans

11,495

23,403

8.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 May 2026 and 31 May 2025:

31.5.26

31.5.25

£

£

Mrs V Patel

Balance outstanding at start of year

17,069

13,119

Amounts advanced

45,566

33,312

Amounts repaid

(38,660

)

(29,362

)

Amounts written off

-

-

Amounts waived

-

-

Balance outstanding at end of year

23,975

17,069

The above loan was unsecured, interest free and repayable on demand.

9.	RELATED PARTY DISCLOSURES

During the year, total dividends of £20,000 (2025 - £13,000) were paid to the directors .